bioAffinity Technologies (BIAF) Invested Capital (2021 - 2026)

bioAffinity Technologies has disclosed Invested Capital across 6 years of filings, most recently posting $4.3 million for Q1 2026.

• In Q1 2026, Invested Capital rose 95.35% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 95.35% YoY), while the FY2025 annual figure was $7.9 million, up 130.98% from the prior year.
• Invested Capital retreated to $4.3 million in Q1 2026, from $7.9 million in the prior quarter.
• Over the last five years, Invested Capital for BIAF reached as high as $22.0 million in Q3 2022 and fell as low as -$16.8 million in Q2 2022.
• The 5-year median for Invested Capital is $6.1 million (2023), against an average of $4.2 million.
• Annual changes were most pronounced in 2022 — Invested Capital surged 261.16% — and 2025, when it tumbled 143.82%.
• A 5-year view of Invested Capital shows it stood at $11.3 million in 2022, then plunged by 46.38% to $6.1 million in 2023, then slumped by 43.17% to $3.4 million in 2024, then jumped by 130.98% to $7.9 million in 2025, then slumped by 46.46% to $4.3 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $4.3 million, $7.9 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.